{"title":"Synthesis, kinetics, mechanisms, and bioactivity evaluations of a novel Zn(II) complex","link":"http://pubs.rsc.org/en/Content/ArticleLanding/2024/RA/D4RA03356F","date":null,"content":"<div><p><img src=\"/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D4RA03356F\" /></p></div><div><i><b>RSC Adv.</b></i>, 2024, <b>14</b>,28693-28702<br /><b>DOI</b>: 10.1039/D4RA03356F, Paper</div><div><img alt=\"Open Access\" src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/open_access_blue.png\" /> Open Access</div><div><a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\"> <img src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/CCBY-NC.png\" alt=\"Creative Commons Licence\" /></a>Â  This article is licensed under a <a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\">Creative Commons Attribution-NonCommercial 3.0 Unported Licence.</a></div><div>Anwesha Dey, Ramesh Kumar, Bhramar Dutta, Rajib Bandopadhyay, Sankha Chakrabortty, Moonis Ali Khan, Rijuta Ganesh Saratale, Ganesh Dattatraya Saratale, Byong Hun Jeon, Alak K. Ghosh<br />Zn(<small>II</small>)-based anticancer drugs can be suitable alternatives to conventional Pt(<small>II</small>)-based drugs because of the unique chemical properties of Zn(<small>II</small>) and low toxicity.<br />The content of this RSS Feed (c) The Royal Society of Chemistry</div>","author":"","siteTitle":"RSC - RSC Adv. latest articles","siteHash":"da3e282678330308414c63a405ade89dd3738fcce2936ca8a2fe3a6d7e967d99","entryHash":"5bdaef974d47b5d126de19700776d1f04510b20b46d343a15a40ecb242abab0f","category":"Environment"}